KCTD15 Protein Expression in Peripheral Blood and Acute Myeloid Leukemia(135 views) Smaldone G, Coppola L, Incoronato M, Parasole R, Ripaldi M, Vitagliano L, Mirabelli P, Salvatore M
Diagnostics (ISSN: 2075-4418linking, 2075-4418electronic), 2020 Jun 4; 10(6): N/D-N/D.
IRCCS SDN, Napoli, Via E. Gianturco 113, 80143 Naples, Italy.
Department of Pediatric Hematology-Oncology, Santobono-Pausilipon Hospital, 80129 Naples, Italy.
Institute of Biostructures and Bioimaging, C.N.R., 80134 Napoli, Italy.
References: Not available.
KCTD15 Protein Expression in Peripheral Blood and Acute Myeloid Leukemia
Leukocytes are major cellular components of the inflammatory and immune response systems. After their generation in the bone marrow from hematopoietic stem cells, they maturate as granulocytes (neutrophils, eosinophils, and basophils), monocytes, and lymphocytes. The abnormal accumulation and proliferation of immature blood cells (blasts) lead to severe and widespread diseases such as leukemia. We have recently shown that KCTD15, a member of the potassium channel tetramerization domain containing protein family (KCTD), is remarkably upregulated in leukemic B-cells. Here, we extend our investigation by monitoring the KCTD15 expression levels in circulating lymphocytes, monocytes, and granulocytes, as well as in leukemia cells. Significant differences in the expression level of KCTD15 were detected in normal lymphocytes, monocytes, and granulocytes. Interestingly, we also found overexpression of the protein following leukemic transformation in the case of myeloid cell lineage. Indeed, KCTD15 was found to be upregulated in K562 and NB4 cells, as well as in HL-60 cell lines. This in vitro finding was corroborated by the analysis of KCTD15 mRNA of acute myeloid leukemia (AML) patients reported in the Microarray Innovations in Leukemia (MILE) dataset. Collectively, the present data open interesting perspectives for understanding the maturation process of leukocytes and for the diagnosis/therapy of acute leukemias.
KCTD15 Protein Expression in Peripheral Blood and Acute Myeloid Leukemia
Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-aranaz F, Di Pompo G, Distel M, Dorado-garcia H, Garcia-castro J, González-gonzález L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-esquivel C, Morales-molina Á, Musa J, Ohmura S, Ory B, Pereira-silva M, Perut F, Rodriguez R, Seeling C, Al Shaaili N, Shaabani S, Shiavone K, Sinha S, Tomazou EM, Trautmann M, Vela M, Versleijen-jonkers YM, Visgauss J, Zalacain M, Schober SJ, Lissat A, English WR, Baldini N, Heymann D * Sarcoma treatment in the era of molecular medicine(125 views) Embo Mol Med (ISSN: 1757-4676linking), 2020 Oct 13; 12(11): e11131-N/D. Impact Factor:10.293 ViewExport to BibTeXExport to EndNote